89 related articles for article (PubMed ID: 23342621)
1. [Serum A1-antitrypsin levels in prostate pathology].
Dokrunova AA; Sokolova OS
Urologiia; 2012; (5):77-80. PubMed ID: 23342621
[TBL] [Abstract][Full Text] [Related]
2. Serum keratinocyte growth factor measurement in patients with prostate cancer.
Mehta PB; Robson CN; Neal DE; Leung HY
J Urol; 2000 Dec; 164(6):2151-5. PubMed ID: 11061946
[TBL] [Abstract][Full Text] [Related]
3. Serum adipocytokine levels in prostate cancer patients.
Arisan ED; Arisan S; Atis G; Palavan-Unsal N; Ergenekon E
Urol Int; 2009; 82(2):203-8. PubMed ID: 19322011
[TBL] [Abstract][Full Text] [Related]
4. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer.
Nagakawa O; Yamagishi T; Fujiuchi Y; Junicho A; Akashi T; Nagaike K; Fuse H
Eur Urol; 2005 Oct; 48(4):686-90. PubMed ID: 16005141
[TBL] [Abstract][Full Text] [Related]
5. [Activity of alpha 1-antitrypsin in blood of patients operated on for tumor and benign hyperplasia of the prostate].
Zietek Z; Iwan-Zietek I; Kotschy M; Tyloch F
Pol Tyg Lek; 1996 Feb; 51(6-9):77-8. PubMed ID: 8756736
[TBL] [Abstract][Full Text] [Related]
6. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
Gao ZW; Liu G; Sheng BW
Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
[TBL] [Abstract][Full Text] [Related]
7. Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Zeng G; Zhong W
Prostate; 2010 Dec; 70(16):1788-98. PubMed ID: 20583137
[TBL] [Abstract][Full Text] [Related]
8. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
9. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
Shannon BA; Cohen RJ; Garrett KL
BJU Int; 2008 Feb; 101(4):429-35. PubMed ID: 17850358
[TBL] [Abstract][Full Text] [Related]
10. Alpha-1 antitrypsin (alpha1-AT) plasma levels in lung, prostate and breast cancer patients.
El-Akawi ZJ; Al-Hindawi FK; Bashir NA
Neuro Endocrinol Lett; 2008 Aug; 29(4):482-4. PubMed ID: 18766166
[TBL] [Abstract][Full Text] [Related]
11. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
[TBL] [Abstract][Full Text] [Related]
12. Immobilization of anti-galectin-3 onto polysiloxane-polyvinyl alcohol disks for tumor prostatic diseases diagnosis.
de Melo-Júnior MR; Araújo-Filho JL; Lins CA; de Pontes-Filho NT; de Carvalho LB
Appl Biochem Biotechnol; 2010 Apr; 160(8):2198-207. PubMed ID: 19728168
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
14. A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia.
Cannon GW; Mullins C; Lucia MS; Hayward SW; Lin V; Liu BC; Slawin K; Rubin MA; Getzenberg RH
J Urol; 2007 Feb; 177(2):610-4; discussion 614. PubMed ID: 17222644
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of plasma interleukin-8 concentration in patients with prostate cancer and benign prostate hyperplasia.
Dehghani M; Mostafavi-Pour Z; Lotfi M; Shakeri S
Iran J Immunol; 2009 Jun; 6(2):92-8. PubMed ID: 19561378
[TBL] [Abstract][Full Text] [Related]
16. [Established oneself the detection of serum prostate specific antigen and application in clinical practice].
Feng T; Dou CQ; Xia TL
Zhonghua Wai Ke Za Zhi; 1994 Nov; 32(11):685-7. PubMed ID: 7539736
[TBL] [Abstract][Full Text] [Related]
17. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
19. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer.
Tahir SA; Ren C; Timme TL; Gdor Y; Hoogeveen R; Morrisett JD; Frolov A; Ayala G; Wheeler TM; Thompson TC
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3653-9. PubMed ID: 14506154
[TBL] [Abstract][Full Text] [Related]
20. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
